Subconjunctival Bevacizumab and Recurrent Pterygium (BRP)

This study has been completed.
Information provided by (Responsible Party):
Instituto de Olhos de Goiania Identifier:
First received: November 29, 2012
Last updated: December 6, 2012
Last verified: December 2012

A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.

Condition Intervention Phase
Recurrent Pterygium
Drug: Bevacizumab
Phase 2
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Interventional Trial of Subconjunctival Bevacizumab in Recurrent Pterygium

Resource links provided by NLM:

Further study details as provided by Instituto de Olhos de Goiania:

Primary Outcome Measures:
  • Pterygium size after subconjunctival bevacizumab [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    -Size of recurrent pterygium (measured in mm) after injection

Secondary Outcome Measures:
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    -Number of patients with hyposphagma and irritative symptoms after subconjunctival injection

Enrollment: 36
Study Start Date: February 2012
Study Completion Date: September 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Subconjunctival Bevacizumab
One aplication of subconjunctival Bevacizumab 0,5 ml
Drug: Bevacizumab
One subconjunctival aplication of Bevacizumabe 0,5ml
Other Name: Avastin

Detailed Description:
  1. Pacients with recurrent pterygium
  2. Anti-VEGF therapy -Bevacizumab

Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Recurrent pterygium

Exclusion Criteria:

  • Pregnant or lactating women
  • History of myocardial infarction
  • History of stroke
  Contacts and Locations
Please refer to this study by its identifier: NCT01744756

Instituto de Olhos de Goiania
Goiania, Goias, Brazil, 74110120
Sponsors and Collaborators
Instituto de Olhos de Goiania
Study Chair: Larissa S Stival, MD Instituto de Olhos de Goiania
  More Information

No publications provided

Responsible Party: Instituto de Olhos de Goiania Identifier: NCT01744756     History of Changes
Other Study ID Numbers: pterygium bevacizumab
Study First Received: November 29, 2012
Last Updated: December 6, 2012
Health Authority: Brazil: Ethics Committee

Keywords provided by Instituto de Olhos de Goiania:
Subconjunctival Bevacizumab
Recurrent pterygium

Additional relevant MeSH terms:
Conjunctival Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses processed this record on April 17, 2014